CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3 + regulatory T cells in the target tissue: Kidney

Transplant Immunology

Volumn 24, Issue 1, 2010, Pages 17-25

  Zhang, Ji Lu ^a,b   Sun, De Jun ^a   Hou, Chun Mei ^b   Wei, Ying Lin ^b   Li, Xin Ying ^b   Yu, Zu Yin ^c   Feng, Jian Nan ^b   Shen, Bei Fen ^b   Li, Yan ^b   Xiao, He ^b  

^a JILIN UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Anti CD3 mAb; CGVHD; Foxp3; Lupus nephritis; Teff Treg balance; Up regulation

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 10; MESSENGER RNA; MONOCLONAL ANTIBODY CD3; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; EFFECTOR CELL; FEMALE; GENE EXPRESSION REGULATION; IMMUNE COMPLEX DEPOSITION; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REGULATORY T LYMPHOCYTE; REMISSION; SHORT COURSE THERAPY; T LYMPHOCYTE ACTIVATION; TARGET ORGAN; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-10; KIDNEY; LUPUS NEPHRITIS; MICE; MICE, INBRED DBA; PROTEINURIA; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 78449260112     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.09.002     Document Type: Article

References (38)

1. lpr mice. J Am Soc Nephrol 2005, 16:3572-3582.
2. Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., Izui S., Wilson C.B., McConahey P.J., et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978, 148:1198-1215.
3. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv Immunol 1985, 37:269-390.
4. Kuppers R.C., Suiter T., Gleichmann E., Rose N.R. The induction of organ-specific antibodies during the graft-vs-host reaction. Eur J Immunol 1988, 18:161-166.
5. Rus V., Svetic A., Nguyen P., Gause W.C., Via C.S. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease: regulatory role of donor CD8+ T cells. J Immunol 1995, 155:2396-2406.
6. Lee S.J. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005, 105:4200-4206.
7. Leo O., Foo M., Sachs D.H., Samelson L.E., Bluestone J.A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987, 84:1374-1378.
8. Hirsch R., Gress R.E., Pluznik D.H., Eckhaus P.M., Bluestone J.A. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989, 142:737-743.
9. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994, 91:123-127.
10. Chatenoud L., Primo J., Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997, 158:2947-2954.
11. Tran G.T., Carter N., He X.Y., Spicer T.S., Plain K.M., Nicolls M., et al. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on Th1 cells that is augmented b IL-4. Int Immunol 2001, 13:1109-1120.
12. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., Chatenoud L. TGF-β dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003, 9:1202-1208.
13. Zhang X., Hupperts R., De Baets M. Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis. Immunol Res 2003, 28:61-78.
14. + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005, 174:4525-4534.
15. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7:622-632.
16. Chavin K.D., Oin L., Lin J., Yagita H., Bromberg J.S. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993, 151:729-759.
17. Blazar B.R., Taylor P.A., Vallerat D.A. In vivo or in vitro anti-CD3ε chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. J Immunol 1994, 152:3665-3674.
18. Thomas F.T., Ricordi C., Contreras J.L., Hubbard W.J., Jiang X.L., Eckhoff D.E., et al. Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999, 67:846-854.
19. Mottram P.L., Murray-segal L.J., Han W., Maguire J., Stein-oakley A.N. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. Transpl Immunol 2002, 10:63-72.
20. Bao L.H., Osawe I., Haas M., Quigg R.J. Signaling through up-reguulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 2005, 175:1947-1955.
21. Stojanovic I., Cvjeticanin T., Lazaroski S., Stosic-Grujicic S., Miljkovic D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 2008, 126:74-83.
22. Deeg H.J., Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Annu Rev Med 1984, 35:11-24.
23. Sullivan K.M., Shulman H.M., Storb R., Weiden P.L., Witherspoon R.P., McDonald G.B., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppresssion. Blood 1981, 57:267-276.
24. Dey B., Sykes M., Spitzer T. Outcomes of recipients of both bone marrow and solid organ transplants: a review. Medicine 1998, 77:355-369.
25. Quranta S., Shulman H., Ahmed A., Shoenfeld Y., Peter J., McDonald G.B., et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 1999, 91:106-116.
26. Slayback D.L., Dobkins J.A., Harper J.M., Allen R.D. Genetic factors influencing the development of chronic graft-versus-host disease in a murine model. Bone Marrow Transplant 2000, 26:931-938.
27. Gleichmann E., Pals S.T., Rolink A.G., Radaszkiewicz T., Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 1984, 5:324-332.
28. Rolink A.G., Gleichmann E. Allosuppressor- and allohelper- T cells in acute and chronic graft-versus-host (GVH) disease, III: different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med 1983, 158:546-558.
29. Sasaki M., Hasegawa H., Kohno M., Inoue A., Ito M.R., Fujita S. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol 2003, 170:588-596.
30. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 43:1051-1057.
31. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
32. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009, 183:3160-3169.
33. Wong C.K., Lit L.C., Tam L.S., Li E.K., Wong P.T., Lam C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127:385-393.
34. Shah K., Lee W.W., Lee S.H., Kim S.H., Kang S.W., Craft J., et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R53.
35. Steffens S., Burger F., Pelli G., Dean Y., Elson G., Kosco-Vilbois M., et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 2006, 114:1977-1984.
36. + T cells. Nat Med 2006, 12:627-635.
37. + follicular helper T cells. J Immunol 2008, 181:6038-6050.
38. Wu H.Y., Center E.M., Tsokos G.C. Weiner HL Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus 2009, 18:586-596.